Member Info for krull

Looking like we may be in an up trend.

Yes, I bought more today, showing as a sell, par for the course here. My one was all the 7s at 12.12

Yes, think the CiRT test is being over looked by the amazing new PSE test.

Should think they selling around 130/140 CiRT test a month by now, with a selling price of $2240 each and a 90% mark up, CiRT could go on to sell 1000 test a month IMO.

Https://youtu.be/ou30IqNMUyA

Https://www.msn.com/en-gb/health/health-news/electrical-prostate-cancer-fix-could-be-offered-to-more-men/ar-AA1eQgtw?ocid=hpmsn&cvid=870d146ca7204d3fba25f1dd2bfe7362&ei=185

Not bad for being negligent, According to a public filing by NatWest in August, Dame Alison has been receiving her annual £2.4m package comprising base salary, pension contribution and a share-based fixed-pay allowance since her departure at the end of July.

She is also eligible to be considered for a pro rata portion of the £2.9m annual bonus and long-term share awards that made up the remainder of her total maximum pay package of £5.3m.

In addition, she holds roughly 2.5 million unvested shares in NatWest, which at Friday's closing share price of 225.9p were worth £5.65m.

That amounts to a theoretical total of nearly £11m, although the fact that Dame Alison left midway through 2023 means she would only have been eligible for just over half of the £2.9m in annual variable pay.

Testpack, A lot of what you say is true, more so from the French, the more a politician from there insults the Brits, the more popular they are.

Looks very hit and miss:

The most accurate way to detect cancer cells inside the prostate gland is the surgical removal and histopathological examination of the entire gland. As this approach is clinically inapplicable to each patient with suspicious findings, prostate biopsy is accepted as the best diagnostic technique to detect prostate cancer. Indeed, the introduction of transrectal ultrasound (TRUS)-guided systematic sextant biopsy method by Hodge and colleagues in 1989 revolutionized the early diagnosis of prostate cancer.1 However, there are two shortcomings of this technique. Firstly, the amount of tissue sampled during prostate biopsy is limited and cancer cells can be missedIn 67.8% of patients, prostate cancer was detected histologically on samples obtained with repeat ex-vivo biopsies, using the same mapping postoperatively. Increase in PSA level, PSA density and biopsy Gleason score, whereas decrease in prostate weight, patient age and free/total PSA ratio

Found this:

Prostate biopsy is usually performed to diagnose or to rule out prostate cancer. A typical biopsy collects about 12 “core” samples from different parts of the prostate to check for abnormal cells. A prostate biopsy is indicated when:

Prostate-specific antigen (PSA) levels are abnormal. Abnormalities are found on a digital rectal examination such as the presence of nodules, hardening of soft tissue, or asymmetry. About 75% of prostate biopsies are negative for cancer. However, prostate biopsies can frequently present with false-negative results, that is, the biopsy does not detect cancer, but cancer is present. In some cases, repeat biopsies may be indicated.

The PSE test at 94% accuracy is more reliable than a biopsy, because early stage PC can be missed if the specimen is taken from the wrong place/side. I can't remember what the failure rate is for a biopsy, but think It's about 25% could be more!

Wow, I dodged a bullet, just looked at CABP, I had 5K in there at £245 share, sold for tiny profit of £55 to buy OBD

What I think is happening, this is being played big time, by traders looking at technical analysis only.

To be honest, I can understand that, with all the skulduggery that goes on, It's probably the only sure way to make any money out of the majority of AIM stocks, so many are life style companies.

However, every now an again, you spot a diamond in the sand, and in my opinion, this is one of them.

You just need to understand the fundamental value here.

Nice find/good info, John:

View organization page: Oxford BioDynamics Plc 2,250 followers 12h

Our company's latest research paper is now one of the most viewed papers in the prestigious Journal, Cancers MDPI, for 2023, a testament to the impact of our work on real-world health!

📖 Titled "Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection," this paper shares groundbreaking results that paved the way for the recently launched EpiSwitch PSE, our 94% accurate #prostatecancer screening test.

📊 The support and interest in our work are truly humbling, and we can't thank our collaborators, peers, and the incredible readership of Cancers enough for their enthusiasm and engagement.

📢 We invite you to read our paper and join the conversation surrounding this game-changing research. Let's continue pushing the boundaries of #precisionmedicine and advancing personalized healthcare together!

Read the paper here: https://lnkd.in/eYRR62qT.

Imperial College London Matt Winkler University of East Anglia Dmitry Pshezhetskiy Imperial College Healthcare NHS Trust #OBD #cancerscreening

Iv'e freed up some cash myself, will buy more if it gets cheaper

Looking at deals with a big phama to fund it!

Presentation

https://youtu.be/c7CQ6qPXvBI

Very significant RNS, the EpiSwitch platform has just been validated by a big independent, no reason why the PSE test won't be next

Phone trade only again

Hold on to your hats

Phone trade only